PRG posts
FeedPosted Jun 22nd 2009 11:40AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Analyst initiations
Analyst Upgrades
- McAdams Wright expects Dendreon's (NASDAQ: DNDN) near-term momentum to continue but has long-term concerns that Street estimates are too high. The firm upgraded shares to Hold from Sell.
- JPMorgan upgraded Ameristar Casinos (NASDAQ: ASCA) to Overweight from Neutral to reflect valuation, potential catalysts from Colorado's easing gaming regulations, and the company's strong free cash flow. The firm raised its target on shares to $24 from $20.
- Citigroup upgraded Valspar (NYSE: VAL) to Hold from Sell after channel checks indicated paint demand is shifting to big-box retailers, the company's primary sales channel. The firm raised its target on shares to $22 from $19.
- Vulcan Materials (NYSE: VMC) was upgraded to Buy from Neutral at UBS.
- Altera (NASDAQ: ALTR) was raised to Outperform from Sector Perform at RBC Capital.
- Spectra Energy (NYSE: SEP) was upgraded to Neutral from Sell at Goldman.
Continue reading Analyst upgrades, downgrades and initiations: ALU, BJ, CPB, KMX, PGR
Posted Jul 23rd 2007 10:30AM by Kevin Shult (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Good news, AFLAC Inc (AFL), , Amgen Inc (AMGN)
MOST NOTEWORTHY: Anheuser-Busch (BUD), Imax Corp (IMAX), Amgen (AMGN), Fifth Third Bancorp (FITB) and TiVO (TIVO) were today's noteworthy upgrades:
- Citigroup upgraded shares of Anheuser-Busch (NYSE: BUD) to Hold from Sell as they see a 70% chance of an alliance between Anheuser-Busch and InBev in the next two years; they believe such a merger would create a market leader.
- Merriman upgraded IMAX Corp (NASDAQ: IMAX) to Buy from Neutral after IMAX removed its overhang by completing SEC filings, while fundamentals have remained strong.
- Citigroup upgraded Amgen (NASDAQ: AMGN) to Hold from Sell to reflect the potential for CMS to roll back proposed reimbursement cuts in oncology, an improving risk/reward profile and the potential for positive phase 3 denosumab data by year-end.
- Kaufman upgraded TiVO (NASDAQ: TIVO) to Buy from Sell as indicators of the change in its business model suggest a positive transaction. The firm feels the the EchoStar (DISH) litigation provides an attractive risk/reward potential, creating an attractive entry point...
OTHER UPGRADES:
- Aflac (NYSE: AFL) was upgraded at Lehman to Overweight from Underweight.
- Navteq (NYSE: NVT) was upgraded to Buy from Neutral at UBS.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).
Twitter to make acquisitions, generate revenue in 2010
Cramer on BloggingStocks: The Fed's push for TARP payback 
Hewlett-Packard reports growth in profit and operating margin in Q4
